YouthView: Understanding risk behaviours for meningococcal meningitis among young people

While meningococcal meningitis is relatively uncommon, it is unpredictable, may progress very rapidly and can lead to death in as little as 24 hours from the first symptoms.(1,2) Although only a few of those exposed to the bacteria will actually develop disease, adolescents and young adults are more likely than any other age group to carry the bacteria without showing symptoms, with carriage rates peaking in 19 year olds with almost 1 in 4 (24%) carrying.(3)

This YouthView study was published in 2019, communicating the results of a large, multi-country survey to assess the behaviours linked to meningococcal meningitis risk factors of adolescents and young adults in key European markets: France, Italy, Spain, Greece, and Portugal.

The YouthView (Understanding Risk Behaviours for Meningococcal Meningitis among Young People) survey is based on over 4,500 interviews among adolescents (15-17 years old), young adults (18-24 years old) and parents of adolescents and young adults. The interviews were conducted via an online survey between February and June 2018. The YouthView survey, sponsored by Pfizer Vaccines*, shows that across key European markets, there is a generally poor understanding about the risks for contracting meningococcal meningitis.

Sample quotas (based on 2011 Eurostat census data) were imposed to ensure national representation based on age, gender and region. Corrective weights have been applied to bring the sample in line with the population profile per country, as well as ensuring that each country is represented accordingly for all data points presented at a combined market level.

Ipsos MORI would now like to invite those interested to have full access to the wealth of findings included in our country reports and infographics.

Invasive meningococcal disease, which is caused by meningococcal bacteria, and primarily results in meningitis and/or septicaemia, is referred to here as ‘meningococcal meningitis’.
*Pfizer International Operations, RCS 491 295 671 Paris, France
[1] European Centre for Disease Control (ECDC). Surveillance of invasive bacterial diseases in Europe 2014. Available at: http://ecdc.europa.eu/en/publications/Publications/AER-VPD-IBD-2014.pdf. Accessed January 18, 2018.
[2] World Health Organization. Meningococcal meningitis, fact sheet No.141. Available at: www.who.int/mediacentre/factsheets/fs141/en. Updated November 2015. Accessed December 3, 2017.
[3] Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010; 10(12): 853–861. Available here. Accessed January 18, 2018.

More insights about Health

Society